 This study aims to explore the efficacy and safety of lanreotide Autogel 120 mg administered every 14 days in subjects with grade 1 or 2, metastatic or locally advanced, unresectable pancreatic or intestinal neuroendocrine tumours NETs once they have progressed on the standard dose of lanreotide Autogel 120 mg every 28 days. 